Newron Pharmaceuticals SpA
SIX:NWRN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.23
10.96
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NWRN stock under the Base Case scenario is 3.1 CHF. Compared to the current market price of 7.45 CHF, Newron Pharmaceuticals SpA is Overvalued by 58%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Newron Pharmaceuticals SpA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NWRN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Newron Pharmaceuticals SpA
Balance Sheet Decomposition
Newron Pharmaceuticals SpA
Current Assets | 19.7m |
Cash & Short-Term Investments | 12.6m |
Receivables | 5.2m |
Other Current Assets | 1.9m |
Non-Current Assets | 6.2m |
PP&E | 405k |
Other Non-Current Assets | 5.8m |
Current Liabilities | 28.9m |
Accounts Payable | 2m |
Accrued Liabilities | 3.5m |
Other Current Liabilities | 23.4m |
Non-Current Liabilities | 26.8m |
Long-Term Debt | 26m |
Other Non-Current Liabilities | 885k |
Earnings Waterfall
Newron Pharmaceuticals SpA
Revenue
|
9.1m
EUR
|
Cost of Revenue
|
-471k
EUR
|
Gross Profit
|
8.6m
EUR
|
Operating Expenses
|
-20.2m
EUR
|
Operating Income
|
-11.6m
EUR
|
Other Expenses
|
-4.6m
EUR
|
Net Income
|
-16.2m
EUR
|
Free Cash Flow Analysis
Newron Pharmaceuticals SpA
EUR | |
Free Cash Flow | EUR |
NWRN Profitability Score
Profitability Due Diligence
Newron Pharmaceuticals SpA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Newron Pharmaceuticals SpA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
NWRN Solvency Score
Solvency Due Diligence
Newron Pharmaceuticals SpA's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Score
Newron Pharmaceuticals SpA's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NWRN Price Targets Summary
Newron Pharmaceuticals SpA
According to Wall Street analysts, the average 1-year price target for NWRN is 14.08 CHF with a low forecast of 12.93 CHF and a high forecast of 15.75 CHF.
Dividends
Current shareholder yield for NWRN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 25 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Contact
IPO
Employees
Officers
The intrinsic value of one NWRN stock under the Base Case scenario is 3.1 CHF.
Compared to the current market price of 7.45 CHF, Newron Pharmaceuticals SpA is Overvalued by 58%.